![](/images/graphics-bg.png)
Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration
المؤلفون المشاركون
Oshima, Kumi
Mori, Jinichi
Kimura, Satoshi
Ikezoe, Takayuki
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-07-27
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
T-cell prolymphocytic leukemia (T-PLL) is a rare hematologic cancer with a dismal prognosis.
Although a small number of patients have central nervous system (CNS) involvement, a standard treatment approach for these patients has not been established.
Herein, we present a case of T-PLL with CNS involvement that was treated with a higher dose of intrathecal alemtuzumab than that previously reported.
A 66-year-old man who had T-PLL with CNS involvement was admitted to our hospital.
Intravenously administered alemtuzumab, a monoclonal antibody against the CD52 antigen, successfully reduced leukemia cells in peripheral blood; however, intrathecal treatment with methotrexate, cytarabine, and prednisone had a limited effect on the CNS involvement.
Therefore, we intrathecally injected alemtuzumab as an experimental treatment.
Although we escalated the dose of intrathecal alemtuzumab up to 5 mg, no adverse reaction was noted; however, this treatment did not completely clear the leukemia cells from the patient’s cerebrospinal fluid (CSF).
We performed whole brain and whole spinal irradiation therapies and subsequently performed allogeneic transplantation from a human leukocyte antigen-matched sibling donor with a conditioning regimen containing total body irradiation.
At 21 days after transplantation, leukemia cells remained in his CSF.
Although intrathecal alemtuzumab did not eliminate the CNS-invading leukemia cells, it was well-tolerated in our case.
Further accumulation of similar cases is needed to determine the benefits and safety of intrathecal alemtuzumab administration.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mori, Jinichi& Oshima, Kumi& Kimura, Satoshi& Ikezoe, Takayuki. 2020. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology،Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mori, Jinichi…[et al.]. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology No. 2020 (2020), pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mori, Jinichi& Oshima, Kumi& Kimura, Satoshi& Ikezoe, Takayuki. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology. 2020. Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1147792
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)